<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED"><gtr:id>6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED</gtr:id><gtr:name>Technical University Dresden</gtr:name><gtr:address><gtr:line1>TU Dresden</gtr:line1><gtr:postCode>D-01062</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>Sch of Molecular Medical Sciences</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED"><gtr:id>6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED</gtr:id><gtr:name>Technical University Dresden</gtr:name><gtr:address><gtr:line1>TU Dresden</gtr:line1><gtr:postCode>D-01062</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7DFF437E-26C2-4E70-8593-F11C4911A093"><gtr:id>7DFF437E-26C2-4E70-8593-F11C4911A093</gtr:id><gtr:firstName>Hester</gtr:firstName><gtr:otherNames>Ann</gtr:otherNames><gtr:surname>Franks</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900336"><gtr:id>8D84DE58-0FC8-4F36-88B8-7D9F758BBFB9</gtr:id><gtr:title>Therapeutic targeting of C-type lectin receptor and MAPK signalling to restore dendritic cell function in cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0900336</gtr:grantReference><gtr:abstractText>Cancer suppresses the body?s immune defences allowing tumours to grow more rapidly and preventing therapeutic cancer vaccines from working effectively. 

The focus of my research is to discover the ways cancer prevents effective immune responses in patients and study approaches to overcome this. We have already shown that cancer cells inhibit a particular signalling protein in a crucial part of the immune system called dendritic cells (DC). Using a specific drug that reverses this we can prevent cancer cells from suppressing DC. Our aim is to develop this concept further using DC from patients with cancer with a view to developing the clinical application of this approach. We will study this class of drug, in collaboration with AstraZeneca who are currently testing them in the clinic for a different purpose. We will also use a range of molecular techniques to dissect the relevant cell signalling pathways.

The proposal brings together leading research groups with complementary expertise to find new ways of enhancing the body?s immune defences. This approach has promise not just for cancer, but also for a range of infectious diseases.</gtr:abstractText><gtr:technicalSummary>Dendritic cells (DC) are pivotal for regulating and priming immunity to cancer and are thus key targets for tumour-mediated immune evasion. Effective therapeutic strategies aimed at restoring immune function have yet to be devised. C-type lectin receptors (CLR) on DC bind a range of glycoproteins including those from pathogens (HIV, TB, HCV) and tumour cells. Binding to CLR triggers a signalling cascade involving mitogen activated protein kinases (MAPK). We have shown inhibitors of MAPK can restore tumour-suppressed function in DC and now have evidence that tumours mediate immune suppression through the CD209 CLR.

Aims: I aim to test the following hypotheses:
1) Manipulation of MAPK signalling in DC reverses tumour-mediated immune suppression.
2) Tumours mediate immune suppression through CLR receptors on DC and this can be reversed by targeting MAPK pathways.

Objectives: 
1) To show that MAPK manipulation can overcome melanoma-mediated immune suppression. 
2) To demonstrate the therapeutic potential of MAPK manipulation in DC from cancer patients.
3) To establish the contribution of specific CLR in tumour-mediated DC suppression.

Design and methodology:
The MAPK signalling pathways of human and murine DC will be altered using two complementary approaches; small molecule inhibitors and recombinant lentiviral vectors (MAPK mutants). Their response to tumours will be characterised using in vitro models where cytokine production, phenotype, migration and T-cell priming will be measured.

The importance of our initial findings will be extended using in vivo and ex vivo systems in mice and man respectively. Mice will be vaccinated with tumour-conditioned or MAPK-inhibited tumour-conditioned DC. Subsequent immune responses and protection against tumour-challenge will be determined. The ability of these strategies to overcome immune suppression in DC from patients with melanoma will be assessed ex vivo.

Our current studies show a role for the CD209 CLR in tumour-mediated DC suppression. The relative contribution of a panel of myeloid CLR will be measured using two complementary approaches. CLR will be knocked-out with siRNA prior to generation of DC (human) and DC will be generated from knock-out mice lacking a panel of CLR.

Scientific and medical opportunities:
If successful this proposal could lead to a novel strategy for improving vaccines, both in cancer and a range of infectious diseases. Agents targeting the MAPK pathways are already in clinical use and this strategy can therefore be rapidly taken forward to clinical testing. Improved understanding of the role of CLR will identify new potential targets for overcoming immune suppression.</gtr:technicalSummary><gtr:fund><gtr:end>2012-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>197045</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Dresden</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Collaboration-Dresden</gtr:description><gtr:id>69FCD519-E3B8-4613-BD8A-AA80517A9BB0</gtr:id><gtr:impact>Journal paper in preparation currently</gtr:impact><gtr:outcomeId>5461d59310e552.03575079-1</gtr:outcomeId><gtr:partnerContribution>Reagents and protocols for isolation of slanDC, DC:T cell coculture experiments after manipulation of intracellular signalling pathways using small molecule inhibitor drugs provided by us.</gtr:partnerContribution><gtr:piContribution>We have provided expertise and reagents on intracellular signalling pathways in dendritic cells. We have carried out in vitro isolation and culture experiments and western blotting on slanDC.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radboud University Nijmegen Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Collaboration-Nijmegen</gtr:description><gtr:id>A769AD3E-918F-438E-8FB2-DEF419D75950</gtr:id><gtr:impact>Journal paper in development</gtr:impact><gtr:outcomeId>546279bc9ebf55.16528844-1</gtr:outcomeId><gtr:partnerContribution>Experiments using small molecule inhibitor drugs on plasmacytoid DC</gtr:partnerContribution><gtr:piContribution>Small molecule inhibitor drugs and instructions regarding use</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration-UCL</gtr:description><gtr:id>A0E80D5C-9713-4773-BC41-7B59411E3D4B</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>546273b2bdb2b6.93129438-1</gtr:outcomeId><gtr:partnerContribution>Samples from a clinical trial of DC immunotherapy for analysis in our laboratory (leucopharesis products, autologous tumour)</gtr:partnerContribution><gtr:piContribution>Dialogue regarding DC immunotherapy and intracellular signalling</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>Melanoma Group</gtr:department><gtr:description>Membership of EORTC melanoma group and Young Investigator Network</gtr:description><gtr:id>C3CCF6F9-0E1B-4C2C-898E-9A0DDAF1F807</gtr:id><gtr:impact>No concrete outputs as yet</gtr:impact><gtr:outcomeId>HnyN4Fvy1E7-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input from other group members</gtr:partnerContribution><gtr:piContribution>Participation at EORTC melanoma group meetings, involvement in design of translational research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Meeting with charitable funders (Matt's Trust)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D3AAF20F-4E3A-4799-875C-25BF0F50C99C</gtr:id><gtr:impact>Representatives from Matt's Trust came to the department to discuss how their charitable donations were being used for our research. I presented my ongoing research plans and was part of a more general discussion about cancer immunotherapy and their public education efforts regarding sun awareness and melanoma.</gtr:impact><gtr:outcomeId>56de9e7ede6119.37578720</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newsletter for charity fundraisers</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2E452920-BF0D-4C0C-8BDB-7C9A73534C4A</gtr:id><gtr:impact>Newsletter distributed to a fundraising group which raises significant funds for our department

Ongoing donations from this fundraising group</gtr:impact><gtr:outcomeId>PMVJ4UM5YzD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nottingham University Impact campaign</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D6727B14-AD31-4D90-9FEE-7AC6A660A750</gtr:id><gtr:impact>Leaflet and stall at Impact campaign launch day, to generate further funding for research

Significant new funding received by the department.</gtr:impact><gtr:outcomeId>BvSinxha2kS</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BSI travel fellowship</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>British Society For Immunology</gtr:fundingOrg><gtr:id>5641A8F0-502F-4B60-AF84-DB8BE3EEE218</gtr:id><gtr:outcomeId>U7Vfd2xaCvr</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>225000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR Clinical Lecturer</gtr:description><gtr:end>2022-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>8E7EFB57-43AE-48C6-992D-1CD6757C98F9</gtr:id><gtr:outcomeId>56de9f69ebc2f0.08822056</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BSI congress bursary</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>British Society For Immunology</gtr:fundingOrg><gtr:id>1ACA01C7-A61A-4043-A482-955DA158B9A1</gtr:id><gtr:outcomeId>HfBpepAKzwJ</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2010-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>91000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>McPhail charity</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>D D McPhail Charitable Settlement</gtr:fundingOrg><gtr:id>C1331408-6A38-414F-BFCB-3AD9D2335B60</gtr:id><gtr:outcomeId>GK5WDBi2snd</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BACR travel bursary</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>British Association for Cancer Research (BACR)</gtr:fundingOrg><gtr:id>DA19A066-9023-49A3-AC52-643922441CF4</gtr:id><gtr:outcomeId>hBykhrD6m31</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>962D1840-62DC-4920-986E-E4828FCFFC9D</gtr:id><gtr:title>Role of mitogen-activated protein kinase and PI3K pathways in the regulation of IL-12-family cytokines in dendritic cells and the generation of T H-responses.</gtr:title><gtr:parentPublicationTitle>European cytokine network</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69d6b12c9da8b2080b1923affecdb87d"><gtr:id>69d6b12c9da8b2080b1923affecdb87d</gtr:id><gtr:otherNames>Jackson AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1148-5493</gtr:issn><gtr:outcomeId>TtXwyQuGPf1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A77C2B0-9452-4EA5-B811-31888910B58F</gtr:id><gtr:title>Impact of p38 mitogen-activated protein kinase inhibition on immunostimulatory properties of human 6-sulfo LacNAc dendritic cells.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f551e0bae741f0853ade90568be7857f"><gtr:id>f551e0bae741f0853ade90568be7857f</gtr:id><gtr:otherNames>Langosch S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>56de9cc76a5791.93352009</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1987A879-F987-48F0-989B-16BEC43FC86C</gtr:id><gtr:title>New anticancer immunotherapies.</gtr:title><gtr:parentPublicationTitle>Anticancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3482145f35e2421667b5dfb612534e99"><gtr:id>3482145f35e2421667b5dfb612534e99</gtr:id><gtr:otherNames>Franks HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0250-7005</gtr:issn><gtr:outcomeId>pm_15053_23_22753700</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACD23AEF-F953-4715-99C1-BBFB4BD36315</gtr:id><gtr:title>Stromal fibroblasts support dendritic cells to maintain IL-23/Th17 responses after exposure to ionizing radiation.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6955e6122bf6ea23398913accaa87ebf"><gtr:id>6955e6122bf6ea23398913accaa87ebf</gtr:id><gtr:otherNames>Malecka A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>58c30b07d16029.98138113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03A2C1D7-C7FF-47B2-B044-5045311A1DE2</gtr:id><gtr:title>Novel function for the p38-MK2 signaling pathway in circulating CD1c+ (BDCA-1+) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL-10.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3482145f35e2421667b5dfb612534e99"><gtr:id>3482145f35e2421667b5dfb612534e99</gtr:id><gtr:otherNames>Franks HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>pm_15053_23_23901045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>084A7B08-537A-4D22-869C-7C404EC50162</gtr:id><gtr:title>The ataxia telangiectasia mutated kinase pathway regulates IL-23 expression by human dendritic cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85103be6c0a7ff70942dad56b4330959"><gtr:id>85103be6c0a7ff70942dad56b4330959</gtr:id><gtr:otherNames>Wang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15053_23_23460736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B0ABA54-9CB0-42D8-A8EF-0A9D68673E09</gtr:id><gtr:title>Novel approach for interleukin-23 up-regulation in human dendritic cells and the impact on T helper type 17 generation.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85103be6c0a7ff70942dad56b4330959"><gtr:id>85103be6c0a7ff70942dad56b4330959</gtr:id><gtr:otherNames>Wang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>rgwmC8LP5Yy</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900336</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>